|Bid||2.15 x 1200|
|Ask||2.17 x 1300|
|Day's range||2.14 - 2.21|
|52-week range||0.93 - 3.75|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.00|
Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity Pharmaceuticals (INFI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.
Investors in Infinity Pharmaceuticals (INFI) need to pay close attention to the stock based on moves in the options market lately.
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 14 cents. For the year, the company reported that its loss widened to $41.8 million, or 83 cents per share. Revenue ...
Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 14 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...